Reynolds, Charles H.

The role of ligand efficiency metrics in drug discovery

Hopkins, A. L., Keserü, G. M., Leeson, P. D., Rees, D. C., & Reynolds, C. H. (2014) · Nature Reviews Drug Discovery

Computational Drug Discovery MethodsChemical Synthesis and Analysis

Cited by 1,181

Discovery of 2-[3,5-Dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β Agonist in Clinical Trials for the Treatment of Dyslipidemia

Kelly, M. J., Pietranico-Cole, S., Larigan, J. D., Haynes, N.-E., Reynolds, C. H., Scott, N., Vermeulen, J., Dvorozniak, M., Conde-Knape, K., Huang, K.-S., et al. (2014) · Journal of Medicinal Chemistry

Thyroid Disorders and TreatmentsSynthesis and Characterization of Heterocyclic Compounds

Cited by 231

Ligand efficiency and fragment-based drug discovery

Bembenek, S. D., Tounge, B. A., & Reynolds, C. H. (2009) · Drug Discovery Today

Computational Drug Discovery MethodsChemical Synthesis and Analysis

Cited by 196